Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. demonstrates strong growth potential, with projections indicating that WAKIX sales in narcolepsy could surge from approximately $160 million in 2020 to over $700 million by 2024, driven by the drug's safety and convenience advantages. Additionally, the company's promising pipeline includes innovative candidates like pitolisant-GR, which is designed to enhance treatment adherence among patients by eliminating dose titration, potentially leading to a new drug application filing in early 2026. Furthermore, Harmony's strategic patent filings could extend exclusivity for its products through 2044, ensuring long-term value and a robust market position beyond the anticipated 2030 loss of exclusivity for WAKIX.

Bears say

Harmony Biosciences Holdings Inc. faces significant risks that contribute to a negative outlook on its stock. The potential entry of new competitors in the sodium oxybate market, combined with a slower-than-expected rate of new patient additions for WAKIX, could hinder the product's growth trajectory. Additionally, the uncertainty surrounding the outcomes of ongoing clinical trials for various indications raises concerns about the company's ability to expand its pipeline successfully.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of Apr 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.